Depressive Disorder
📧 Sign up to get email alerts when something new happens for Depressive Disorder.
Sign up freeTop drugs studied for this disease
-
EMA safety_alert · 2014-09-26EMA confirms positive benefit-risk for antidepressant Valdoxan/Thymanax (agomelatine)
The EMA confirms a positive benefit-risk profile for agomelatine (Valdoxan/Thymanax) as an antidepressant after evaluating available data.